Total Voting Rights

Rhea-AI Summary

Amryt announces that as of August 31, 2021, its total issued share capital comprises 316,496,087 ordinary shares. No shares are held in treasury, leading to the total number of voting rights also being 316,496,087. This figure is essential for shareholders to determine any required notifications under the FCA’s Disclosure Guidance and Transparency Rules.

Amryt focuses on developing treatments for rare diseases and has several approved products including Myalept, Mycapssa, and Juxtapid. The company is also awaiting FDA approval for its lead candidate, Oleogel-S10 (Filsuvez), with a PDUFA date set for November 30, 2021.

Positive

• The company has a solid issued share capital of 316,496,087 ordinary shares, providing transparency in total voting rights.
• Amryt has multiple approved orphan disease products, showcasing a diverse portfolio in rare disease treatments.
• The NDA submission for Oleogel-S10 (Filsuvez) has been accepted by the FDA, indicating progress in potential new treatments.

Negative

• None.

Total Voting Rights

DUBLIN, Ireland, and Boston MA, September 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on August 31, 2021 the issued share capital of the Company comprised 316,496,087 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at August 31, 2021 was 316,496,087. 

This figure of 316,496,087 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

About Amryt
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

Amryt’s commercial business comprises three orphan disease products – metreleptin (Myalept®/ Myalepta®); octreotide (Mycapssa®); and lomitapide (Juxtapid®/ Lojuxta®).

Myalept®/Myalepta® (metreleptin) is approved in the US (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta®) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. For additional information, please follow this link.

Mycapssa® (octreotide) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only oral somatostatin analog approved by the FDA. Mycapssa® has also been submitted to the EMA for regulatory approval. For additional information, please follow this link.

Juxtapid®/Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid®) and in the EU, Israel and Brazil (under the trade name Lojuxta®). For additional information, please follow this link.

Amryt's lead development candidate, Oleogel-S10 (Filsuvez®) is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Filsuvez® has been selected as the brand name for Oleogel-S10. The product has been submitted to FDA for approval and in June 2021, Amryt received confirmation from the FDA that its NDA for Oleogel-S10 had been accepted and granted priority review. The FDA also set a target PDUFA date of November 30, 2021.

Amryt’s pre-clinical gene therapy candidate, AP103, offers a potential treatment for patients with Dystrophic EB, and the polymer-based delivery platform has the potential to be developed for the treatment of other genetic disorders.

Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE^®) technology platform.

For more information on Amryt, including products, please visit www.amrytpharma.com.

Contacts

Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com

Edward Mansfield, Shore Capital, NOMAD +44 (0) 207 408 4090, edward.mansfield@shorecap.co.uk

Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com

Amber Fennell, Consilium Strategic Communications, +44 (0) 203 709 5700, fennell@consilium-comms.com

FAQ

What is the total number of voting rights for Amryt as of August 31, 2021?

The total number of voting rights for Amryt as of August 31, 2021, is 316,496,087.

When is the PDUFA date for Oleogel-S10 (Filsuvez)?

The PDUFA date for Oleogel-S10 (Filsuvez) is set for November 30, 2021.

What are Amryt's approved orphan disease products?

Amryt's approved orphan disease products include Myalept (metreleptin), Mycapssa (octreotide), and Juxtapid (lomitapide).

What is the significance of the issued share capital of 316,496,087 for Amryt?

The issued share capital of 316,496,087 ordinary shares helps shareholders determine if they need to notify any interest changes under the FCA’s rules.